Effects and safety of iron therapy in patients with chronic heart failure and iron deficiency:a meta-analysis of randomized controlled trials
Wen-xiao WANG,Xian YANG,Hai-ying ZHONG,Yun FANG
DOI: https://doi.org/10.13286/j.cnki.chinhosppharmacyj.2018.16.12
2018-01-01
Abstract:OBJECTIVE To review the effects and safety of iron therapy in chronic heart failure with iron deficiency patients.METHODS Related randomized controlled clinical trials (RCTs) about iron therapy in chronic heart failure with iron deficiency patients were collected and selected according to inclusion and exclusion criterions.The effects and safety of iron therapy were compared by using the meta analysis.RESULTS Eight trials were included.The quality of the included studies was high.Efficacy:intravenous or oral iron could not increase the hemoglobin[OR=0.71, 95％CI (-0.08, 1.50), P=0.08], but improve the serum ferritin (SF) [OR=175.18, 95％CI (118.54, 231.83), P＜0.01]and transferrin saturation (TSAT);oral iron could not improve the peak VO2 [OR=0.19, 95％CI (-0.27, 0.65), P=0.42], NT-proBNP [OR=41.00, 95％CI (-95.54, 177.54), P=0.56], KCCQ [OR=6.02, 95％CI (2.62, 9.43), P＜0.01], but intravenous iron increased those outcomes[OR=1.33, 95％CI (0.60, 2.06), P＜0.01], [OR=-517.99, 95％CI (-764.88,-271.11), P＜0.01]and [OR=6.02, 95％CI (2.62, 9.43), P＜0.01].Safety:intravenous or oral iron did not increased adverse event[OR=0.98, 95％CI (0.74, 1.29), P=0.88], all-cause death or cardiovascular hospitalization [OR=0.75, 95％CI (0.42, 1.33), P=0.32], all-cause death [OR=0.76, 95％CI (0.43, 1.35), P=0.34], and hospitalization [OR=1.1, 95％CI (0.49, 2.51), P=0.82].CONCLUSION Both intravenous and oral iron preparations have good safety for patients with chronic heart failure combined iron deficiency.Intravenous iron is more effective than oral iron.